You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letters
Sildenafil in bronchopulmonary dysplasia: safe to use?
  1. Andrew James Wardle1,
  2. Georgia May Connolly2,
  3. Tom Stonier3,
  4. Robert Tulloh4
  1. 1Department of Paediatrics, Imperial College, London, UK
  2. 2Department of Paediatrics, Bristol Royal Hospital for Children, Bristol, UK
  3. 3North West Thames Foundation School, London, UK
  4. 4Department of Cardiology, Bristol Royal Hospital for Children, Bristol, UK
  1. Correspondence to Professor Robert Tulloh, Department of Cardiology, Bristol Royal Hospital for Children, Research Floor Level 7, Queens Building, Bristol Royal Infirmary, Bristol BS2 8HW, UK; Robert.Tulloh{at}Bristol.ac.uk

https://doi.org/10.1136/archdischild-2015-308164

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    One-third of preterm infants are diagnosed with bronchopulmonary dysplasia (BPD), a complex multifactorial disorder associated with significant morbidity. Associated pathologies include pulmonary hypertension (PH), a critical cardiorespiratory pathology with 48% 2-year mortality that affects up to a third of infants with BPD.1 Pulmonary vasodilatation in PH prolongs life, and phosphodiesterase-V inhibition is the primary approach for this.2 That stated, current evidence is limited to 45 patients across five case series.3 They demonstrate a reduction in overall mortality to 18%, but reservations remain regarding safety and efficacy.

    We therefore conducted a retrospective investigation into patients with BPD–PH managed at our centre between August 2008 and July …

    View Full Text

    Footnotes

    • Contributors All authors made substantial contributions to the conception of the work and the acquisition, analysis or interpretation of data; drafted the work and approved the version submitted for publication.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.